X-19360666-C-A

Position:

• chrX-19360666-C-A

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_Strong BP6_Very_Strong BA1

The NM_001001671.4(MAP3K15):​c.*83G>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0904 in 709,368 control chromosomes in the GnomAD database, including 8,548 homozygotes. There are 19,538 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

• Frequency:
  • Genomes: 𝑓 0.22 (5000 hom., 7078 hem., cov: 24)
  • Exomes 𝑓: 0.066 (3548 hom. 12460 hem.)
• Consequence: MAP3K15 NM_001001671.4 3_prime_UTR
• Clinical Significance: Benign criteria provided, multiple submitters, no conflicts B:2
• Conservation: PhyloP100: -0.236

Genes affected

PDHA1 (HGNC:8806): (pyruvate dehydrogenase E1 subunit alpha 1) The pyruvate dehydrogenase (PDH) complex is a nuclear-encoded mitochondrial multienzyme complex that catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and provides the primary link between glycolysis and the tricarboxylic acid (TCA) cycle. The PDH complex is composed of multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). The E1 enzyme is a heterotetramer of two alpha and two beta subunits. This gene encodes the E1 alpha 1 subunit containing the E1 active site, and plays a key role in the function of the PDH complex. Mutations in this gene are associated with pyruvate dehydrogenase E1-alpha deficiency and X-linked Leigh syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Mar 2010]

MAP3K15 (HGNC:31689): (mitogen-activated protein kinase kinase kinase 15) The protein encoded by this gene is a member of the mitogen-activated protein kinase (MAPK) family. These family members function in a protein kinase signal transduction cascade, where an activated MAPK kinase kinase (MAP3K) phosphorylates and activates a specific MAPK kinase (MAP2K), which then activates a specific MAPK. This MAP3K protein plays an essential role in apoptotic cell death triggered by cellular stresses. [provided by RefSeq, Jul 2010]

ACMG classification

Verdict is Benign. Variant got -20 ACMG points.

• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.83).
• BP6: Variant X-19360666-C-A is Benign according to our data. Variant chrX-19360666-C-A is described in ClinVar as [Benign]. Clinvar id is 914971.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
• BA1: GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.649 is higher than 0.05.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
PDHA1	NM_000284.4	c.*1013C>A		3_prime_UTR_variant	11/11	ENST00000422285.7
MAP3K15	NM_001001671.4	c.*83G>T		3_prime_UTR_variant	29/29	ENST00000338883.9

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
MAP3K15	ENST00000338883.9	c.*83G>T		3_prime_UTR_variant	29/29	5	NM_001001671.4	P1
PDHA1	ENST00000422285.7	c.*1013C>A		3_prime_UTR_variant	11/11	1	NM_000284.4	P1

Frequencies

GnomAD3 genomes AF: 0.217 AC: 24408 AN: 112235 Hom.: 4997 Cov.: 24 AF XY: 0.205 AC XY: 7041 AN XY: 34423

Gnomad AFR AF: 0.657

Gnomad AMI AF: 0.113

Gnomad AMR AF: 0.0991

Gnomad ASJ AF: 0.113

Gnomad EAS AF: 0.00497

Gnomad SAS AF: 0.143

Gnomad FIN AF: 0.0323

Gnomad MID AF: 0.211

Gnomad NFE AF: 0.0347

Gnomad OTH AF: 0.193

GnomAD4 exome AF: 0.0664 AC: 39665 AN: 597079 Hom.: 3548 Cov.: 9 AF XY: 0.0722 AC XY: 12460 AN XY: 172687

Gnomad4 AFR exome AF: 0.671

Gnomad4 AMR exome AF: 0.0694

Gnomad4 ASJ exome AF: 0.113

Gnomad4 EAS exome AF: 0.00485

Gnomad4 SAS exome AF: 0.155

Gnomad4 FIN exome AF: 0.0365

Gnomad4 NFE exome AF: 0.0364

Gnomad4 OTH exome AF: 0.0995

GnomAD4 genome AF: 0.218 AC: 24452 AN: 112289 Hom.: 5000 Cov.: 24 AF XY: 0.205 AC XY: 7078 AN XY: 34487

Gnomad4 AFR AF: 0.657

Gnomad4 AMR AF: 0.0990

Gnomad4 ASJ AF: 0.113

Gnomad4 EAS AF: 0.00498

Gnomad4 SAS AF: 0.144

Gnomad4 FIN AF: 0.0323

Gnomad4 NFE AF: 0.0347

Gnomad4 OTH AF: 0.191

Alfa AF: 0.0651 Hom.: 1251

Bravo AF: 0.243

ClinVar

Significance: Benign

Submissions summary: Benign:2

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Pyruvate dehydrogenase E1-alpha deficiency Benign:1

Benign, criteria provided, single submitter

clinical testing

Illumina Laboratory Services, Illumina

Jan 12, 2018

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:1

Benign, criteria provided, single submitter

not provided

Breakthrough Genomics, Breakthrough Genomics

-

- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.83
CADD	Benign	0.91
DANN	Benign	0.49

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs1042456; hg19: chrX-19378784;